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The juxtaglomerular (JG) cell product renin is rate limiting in
the generation of the bioactive octapeptide angiotensin II.
Rates of synthesis and secretion of the aspartyl protease
renin by JG cells are controlled by multiple afferent and
efferent pathways originating in the CNS, cardiovascular
system, and kidneys, and making critical contributions to the
maintenance of extracellular fluid volume and arterial blood
pressure. Since both excesses and deficits of angiotensin II
have deleterious effects, it is not surprising that control of
renin is secured by a complex system of feedforward and
feedback relationships. Mice with genetic alterations have
contributed to a better understanding of the networks
controlling renin synthesis and secretion. Essential input for
the setting of basal renin generation rates is provided by
b-adrenergic receptors acting through cyclic adenosine
monophosphate, the primary intracellular activation mech-
anism for renin mRNA generation. Other major control mech-
anisms include COX-2 and nNOS affecting renin through
PGE2, PGI2, and nitric oxide. Angiotensin II provides strong
negative feedback inhibition of renin synthesis, largely an
indirect effect mediated by baroreceptor and macula densa
inputs. Adenosine appears to be a dominant factor in the
inhibitory arms of the baroreceptor and macula densa
mechanisms. Targeted gene mutations have also shed light
on a number of novel aspects related to renin processing and
the regulation of renin synthesis and secretion.
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The antihypertensive, antifibrotic, and antiproliferative
effects of systemic administration of inhibitors of renin,
angiotensin II receptors, or angiotensin II–converting enzyme
underscore the important contribution of the renin–angio-
tensin system (RAS) to the progression of cardiovascular and
renal diseases. The formation of angiotensin II in the
circulation is primarily regulated by changes in the activity
of the aspartyl protease renin, which is largely a product of
the juxtaglomerular (JG) granular cells at the glomerular
vascular pole of the kidney. Thus, the rate of renin synthesis
in JG cells and the rate of renin secretion are the main
determinants of circulating angiotensin II. Under steady-state
conditions, synthesis and secretion of renin tend to change in
parallel as transcriptional and posttranscriptional regulation
of renin mRNA and secretion of renin from storage granules
are partly under the control of the same intracellular
mechanisms.
Commensurate with the central role of angiotensin II in
volume homeostasis, synthesis and secretion of renin by JG
cells is regulated by multiple inputs that in general reflect the
status of extracellular fluid volume. The most important
among the macroscopic control mechanisms of renin release
in vivo are blood pressure (‘the renal baroreceptor mechan-
ism’), renal sympathetic tone through b-adrenergic receptors,
and tubular NaCl concentration in the macula densa segment
of the nephron (‘the macula densa mechanism’). A number
of pharmacological, ablative, and cellular strategies have been
used to establish the distinct nature and contribution of
individual regulatory pathways in controlling renin secretion.
However, the cellular mechanisms underlying control of
renin secretion by physiological regulatory systems in the
intact animal have been difficult to identify because of
complex interactions between feedforward and feedback
regulation. Mice with defined gene manipulations offer a
new venue to further explore the mechanisms responsible for
control of renin synthesis and secretion in the intact
organism. The approach in the majority of studies has been
to draw conclusions from phenotypic changes caused by
defined alterations of the genotype. In this review, we will
focus mostly on those studies of renin secretion in which
interference with recognized signaling pathways has occurred
at the level of receptors, ligands, ligand synthesis, and
membrane transduction mechanisms, all interventions that
http://www.kidney-international.org rev iew
& 2012 International Society of Nephrology
Received 7 July 2011; revised 30 August 2011; accepted 20 September
2011; published online 18 January 2012
Correspondence: Jurgen Schnermann, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive-
MSC 1370, Bethesda, Maryland 20892, USA.
E-mail: jurgens@intra.niddk.nih.gov
Kidney International (2012) 81, 529–538 529
could potentially shed light on the acute regulation of renin
release. A graphical preview of the selected topics is given in
Figure 1.
It has become apparent that the generation of angiotensin
II in the circulation is only part of the functionality of the
RAS. Evidence is mounting that angiotensin II can be
generated in a tissue-specific manner and exert local effects,
for example, in the brain, heart, or kidney, but a discussion of
these local effects will not be attempted here.1,2 Furthermore,
in this short review, we cannot address the important
progress that has been made in defining the sequences in the
renin DNA and their binding complexes that promote,
enhance, or silence renin gene transcription, for example, by
the activation of nuclear hormone receptors such as the vitamin
D3 receptor or peroxisome proliferator-activated receptor.3–5
ANGIOTENSIN II
Mice with deletions in the non-renin components of the RAS
have confirmed that the expression and secretion of renin is
under strong inhibitory control of angiotensin II. Mice with
null mutations in the genes for angiotensinogen, angiotensin-
converting enzyme, and angiotensin II receptors show
consistent and massive upregulation of renin expression
and plasma renin concentrations.6–11 The overexpression of
renin in these conditions is typically associated with
upstream recruitment and ectopic location of renin-express-
ing cells.7,11–13 Disruption of AT1a signaling contributes
most to these abnormalities; intrarenal renin expression was
found to be essentially normal in AT1b- or AT2-deficient
mice.13,14 In fact, plasma angiotensin II levels were lower in
AT1a/AT1b/AT2 triple knockout mice than in mice with AT1
receptor deficiency, suggesting that AT2 receptors may have
effects that are directionally opposite to those elicited by AT1
receptors.15
It has been a widely accepted notion that the effect of
angiotensin II on renin expression is the reflection of a direct
interaction of the peptide with JG cells. Several findings from
genetically modified mice call this concept into question.
Cross-transplantation of kidneys between AT1a-deficient and
wild-type (WT) mice results in a significant increase in renin
expression only when AT1a receptors are missing in the entire
organism. Selective absence of AT1a receptors in the kidneys
did not cause detectable elevations of renal renin mRNA,
suggesting that upregulation of renin expression is not the
direct consequence of angiotensin withdrawal from AT1
receptors in JG cells.16 That the stimulation of renin
expression by withdrawal of angiotensin II effects is not
primarily mediated by AT1 receptors on JG cells is supported
by earlier findings in chimeric mice carrying both AT1a/
and AT1aþ /þ cells. In these mice, increases in renin
expression and JG cell hyperplasia were seen independent
of whether individual juxta glomerular apparatus did or did
not express AT1 receptors.17 In both studies, increased renin
expression correlated with the reduced arterial blood
pressure, suggesting that at least part of the ‘feedback’ effect
of angiotensin II is baroreceptor mediated. Increased arterial
blood pressure rather than any direct effects of angiotensin II
may also be responsible for the inhibition of renin expression
in angiotensinogen-deficient mice on high salt intake.18–20
G Protein Gsa and cyclic adenosine monophosphate (cAMP)
Substantial early experimental evidence has supported an
important role for Gsa in activating adenylate cyclase (AC)
and stimulating renin synthesis and secretion through its
catalytic product cAMP.21 The absolutely critical contribu-
tion of the Gsa–cAMP–PKA signaling cascade in both basal
and regulated renin secretion has been affirmed in mice with
selective deletion of Gsa in JG cells.22 Cell-specific Gsa
deletion was achieved by crossing mice that express Cre
recombinase under control of the endogenous renin
promoter with animals in which exon 1 of the GNAS gene
is flanked by loxP sites.12,23 In mice homozygous for the loxP-
flanked GNAS gene and heterozygous for the modified renin
locus, native Gsa was found to be significantly reduced in the
whole kidney and almost completely abolished in single JG
cells at the DNA, mRNA, and protein level.22 This genetic
deletion of Gsa in JG cells was associated with a marked
reduction of renin expression and renin secretion under basal
conditions. Renal cortical renin mRNA was reduced to 23%
of control and renin content of isolated JG cells to about 10%
of control, indicating a greatly reduced rate of renin
production. Furthermore, concentrations of renin in plasma
and in the medium of isolated JG cells were reduced to 10%
and 5% of control, respectively, indicating a critical role of
Gsa signaling in renin secretion.22 Thus, Gsa-dependent
































Figure 1 | Schematic overview of the majority of genetic
targets discussed in this review and their effects on renin
release. Oval indicates a representative juxtaglomerular cell and
effects on renin release are indicated by arrows, with solid arrows
delineating direct effects (or stimulatory effects with positive
deflections) and broken arrows indicating inverse effects (or
inhibitory effects with positive deflections). Pathways with an
even number of broken arrows (zero or two) are stimulatory, and
pathways with an uneven number of broken arrows are inhibitory.
A1AR, A1 adenosine receptor subtype; cAMP, cyclic adenosine
monophosphate; cGMP, cyclic guanosine monophosphate; eNOS,
endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase;
NO, nitric acid; PACAP, pituitary adenylate cyclase–activating
polypeptide; PDE3, phosphodiesterase 3; PGE2, prostaglandin E2.
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the maintenance of high basal levels of renin expression and
renin release. Furthermore, the stimulation of renin secretion
caused acutely by furosemide, hydralazine, or isoproterenol
was virtually abolished in the Gsa-deficient mice. To the
extent that furosemide stimulates renin secretion through the
macula densa and hydralazine through the baroreceptor,
these data suggest that Gsa is required for the major
physiological inputs that regulate renin secretion in vivo.
Suppression of renin expression in the absence of Gsa
signaling is already apparent prenatally; the appearance of
renin in distal arcuate arteries, the earliest site for renin
expression in the metanephric kidney, was missing in mice
with JG cell–specific deletion of Gsa.24
A somewhat unexpected observation has been that the
strong stimulation of renin synthesis and secretion caused by
either converting enzyme or angiotensin receptors blockers
was completely abrogated in mice with JG cell–specific
deletion of Gsa.25 This finding sheds additional light on the
phenomenon often described as the ‘short loop feedback’
inhibition of renin expression. Although there is substantial
support for the concept that angiotensin II has a direct
inhibitory effect on JG cells, mediated presumably by an
increase in cytosolic calcium, there is no direct support for
the assumption that the stimulatory pathway is simply the
reverse, that is, caused by a direct effect of angiotensin II on
the JG cells to decrease cellular calcium.26 The requirement
for Gsa for the stimulation of renin release by angiotensin II
withdrawal indicates a role for activation of Gsa-dependent
pathways. Coadministration of propranolol, indomethacin,
and No-nitro-L-arginine methyl ester mimicked the effect of
Gsa deficiency,25 indicating that angiotensin II withdrawal
produces Gsa activation through stimulation of catechol-
amines, prostaglandins, and nitric oxide, and that these agents
are the actual ligands that effect renin stimulation.
CYCLOOXYGENASE AND PROSTAGLANDINS
Studies of the functional connection between renin and the
prostanoid system are founded on the finding that arachi-
donic acid increases and indomethacin reduces plasma renin
levels.27 Numerous subsequent studies have identified various
metabolites of arachidonic acid as potential regulators of
renin secretion,28 with prostaglandins of the E and I series
being the most consistent stimulators of renin release.29
The effects of prostaglandin E2 (PGE2) are elicited by the
activation of four types of G protein–coupled receptors
(EP1–EP4). Studies in mice with deletion of single PGE2
receptors have identified the Gsa-coupled EP4 as the most
important receptor for stimulation of renin. Basal plasma
renin concentration was significantly lower in EP4-deficient
than WT-deficient mice, whereas there was no difference in
EP1-, EP2-, or EP3-deficient mice.30 Renin release in
response to a high PGE2 concentration was significantly
reduced in isolated perfused kidneys of EP4/ and EP2/
mice, whereas the renin-stimulating threshold concentration
was increased in EP4/ mice, suggesting that PGE2 acts
through EP4 and EP2 to increase renin release.30 Stimulation
of renin release by chronic administration of furosemide was
significantly reduced in EP4/ mice together with a reduced
stimulation of renin expression,31 although the acute admini-
stration of bumetanide in isolated kidneys did not show a
difference in the renin release response between EP4/ mice
and all other strains.30 The effect of PGE2 on renin release is
probably a direct effect, as isolated JG cells have been shown
to express EP4 and EP2 mRNA and to respond to PGE2 with
increased renin secretion.29,32 In view of the strong evidence
involving PGE2 in renin secretion, it is surprising that mice
deficient in microsomal PGE2 synthase did not show a
significant reduction in basal or furosemide-stimulated renin
mRNA, suggesting that alternative pathways may exist for the
synthesis of PGE2.33
Studies in prostacyclin receptor (IP)–deficient mice have
confirmed that prostacyclin is another prostaglandin with
renin-stimulatory properties. In addition to having a reduced
response to the stimulatory effect of furosemide, IP-deficient
mice have a markedly reduced response of renin expression
and release in response to renal arterial constriction or salt
depletion, whereas mice with deficiencies in the four PGE2
receptors showed normal responsiveness.31,34 Somewhat
unexpectedly, mice deficient in the FP receptor, the
prostanoid receptor that mediates the effects of PGF2a, also
had reduced levels of plasma renin and angiotensin II
concentrations.35 At the same time, the number of renin-
expressing cells appeared to be reduced, but exactly how
PGF2a may stimulate renin release or increase the number of
JG cells is unknown.
Mice with deletion in PGHS-2 (COX-2) have aided in
solidifying the notion that the formation of PGE2 is a critical
regulatory input to the formation and release of renin by JG
cells. The presence of COX-2 in macula densa and TAL cells
had suggested that this pathway may be of particular
importance for macula densa control of renin.36 Evidence
in support of this notion was provided by studies in COX-2-
deficient mice showing that renin enzyme activity, plasma
renin, and renal renin mRNA and protein expression were
markedly reduced.37–39 In contrast, plasma renin concentra-
tion and renal renin expression were not different from
control in COX-1-deficient mice.40 It is of note that the
stimulatory effect of a chronic low-salt diet on renin
expression was virtually absent in COX-2/ mice.38 The
magnitude of the renin release response to acute stimulation
by furosemide, hydralazine, or isoproterenol was markedly
diminished in the absence of COX-2,37 as it is in most states
of chronically suppressed renin.
It is noteworthy that chronic inhibition of COX-2 enzyme
activity by inhibitors such as rofecoxib does not always
produce the same inhibition of renin expression that is seen
with genetic COX-2 deletion.41,42 A possible explanation for
this dissociation may lie in the observation that pharma-
cological COX-2 inhibition is associated with a marked
upregulation of renal COX-2 expression so that increased
COX-2 enzyme levels may partly compensate for enzyme
blockade.41 Other evidence for unidentified modifying
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factors in this pathway is the observation that the reduction
in plasma renin concentration was more pronounced in mice
with the COX-2 null mutation bred into congenic C57Bl/6,
BALB/c, or 129 J backgrounds compared with that seen in a
mixed genetic background.37,39,43
Studies in COX-2-deficient mice have also provided
insights about another important interaction in the relation-
ships between prostaglandins and renin, the feedback
inhibition of COX-2 expression by angiotensin II (Figure 2).
One critical experimental observation is that inhibition or
genetic deletion of COX-2 attenuates the stimulatory effect of
angiotensin II blockade on renin expression.37,43 No
difference in the stimulatory effect of captopril was observed
between WT and COX-1-deficient mice.40 Thus, a reduction
in angiotensin II signaling, probably at the level of the macula
densa (MD) and/or TAL cells, appears to lessen tonic
feedback inhibition of COX-2 and thereby enhance renin
expression. This is strongly supported by the observation that
COX-2 expression is markedly upregulated in angiotensin
II–blocked or –deficient mice.37,43–47 A fivefold upregulation
of COX-2 and of urinary PGE2 excretion has also been
observed in the low renin model of JG cell–specific deletion of
Gsa.22 Interestingly, whereas AT1a receptors on macula densa
cells appear to mediate inhibition of COX-2 expression, AT2
receptors may cause stimulation of COX-2 expression. This is
based partly on the observation that the AT1 receptor blocker
candesartan elevated COX-2 expression to a lesser extent in
AT2 knockouts than in WT mice.48 Furthermore, the
stimulatory effect of candesartan in WT mice was lessened
by the AT2 receptor blocker PD123319. Thus, although under
most physiological conditions COX-2 and renin expression
change in parallel, during primary changes of renin
expression angiotensin II feedback inhibition of COX-2 can
dissociate the expression of COX-2 and renin.
NITRIC OXIDE (NO)
The notion that NO may contribute to the regulation of renin
secretion has seemed plausible because of the high levels of
expression of NOS in cells of the macula densa and vascular
endothelium, two cell types in close anatomical association
with JG cells. Nevertheless, conclusions from studies with NO
synthase blocking agents have been contradictory. Perhaps
the most convincing evidence for an important role of NOS
in renin secretion comes from studies in isolated perfused
kidneys from either neuronal nitric oxide synthase (nNOS)
or endothelial nitric oxide synthase (eNOS)-deficient mice, in
which renin secretion is markedly reduced (to 10% or 30%,
respectively).49 As perfusion pressure is servo-controlled in
this setting, indirect mediation of the effect of NOS deficiency
on renin by baroreceptor activation is unlikely. In intact
nNOS-deficient mice, plasma renin concentration is reduced,
supporting tonic stimulation of renin secretion by NO.39,49
Furthermore, the stimulation of renin synthesis and secretion
caused by reduced Na intake was absent in mice without
nNOS.50 In contrast to plasma renin, renal renin mRNA
expression and renal renin content were found to be
unchanged in nNOS knockout mice compared with WT
mice.51 The strength of the evidence from these studies is
somewhat marred by the fact that the recombination strategy
used in the available nNOS knockout mice permits the
translation of an enzymatically active NOS1 isoform called
NOS1b.52 This isoform has recently been detected in macula
densa cells, and thus residual NOS activity in the vicinity of
JG cells cannot be excluded in the ‘knockout’ animals.53
Evidence for a role of NO generated by eNOS in basal
renin release is less convincing. Plasma renin concentration
of eNOS-deficient mice was not different from WTs in two
studies49,54 and paradoxically increased in another.55 An
increase in plasma renin concentration accompanied by an
increase in plasma aldosterone was also observed in triple
knockout mice devoid of all three NOS isoforms.56 As these
mice show signs of cardiac and renal failure leading to a
markedly reduced life span, it is likely that a reduction of
renal perfusion overcomes any inhibitory effects of NOS
deficiency on renin release. The observations in the triple
knockouts notwithstanding, renal renin expression and
plasma renin concentration were found to be significantly
reduced in nNOS/eNOS double-knockout mice generated in
our laboratory (unpublished). Furthermore, whereas NOS
inhibition with No-nitro-L-arginine methyl ester reduced
plasma renin in WT, eNOS/, and nNOS/, it had no






















Figure 2 |Angiotensin II feedback inhibition of renin synthesis
and secretion is mediated by AT1 receptors on both
juxtaglomerular (JG) cells and on macula densa cells.
Activation of JG cell receptors directly inhibits renin, whereas
activation of macula densa cell receptors (perhaps also of thick
ascending limb of Henle’s loop (TAL) and vascular smooth muscle
cells (VSMC) receptors) inhibits renin indirectly through
downregulation of COX-2 and nNOS. Feedback inhibition by
angiotensin II is not necessarily symmetrical: reductions of
angiotensin II levels rely more exclusively on the indirect
pathways than increases of angiotensin II. Solid arrows denote
direct relationships or positive effects, whereas broken arrows
denote inverse relationships or negative effects. ACE, angiotensin-
converting enzyme; AC5/6, adenylyl cyclase 5 or 6; AGT,
angiotensinogen; cAMP, cyclic adenosine monophosphate; nNOS,
neuronal nitric oxide synthase; PDE3, phosphodiesterase 3; PGE2,
prostaglandin E2.
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that iNOS does not have a major role under normal condi-
tions and that both eNOS and nNOS facilitate renin release.
Expression of nNOS in macula densa cells was observed to
be significantly increased in mice with gene deletions of the
AT1a receptor, of both AT1a and AT1b receptors, and of
angiotensinogen, suggesting that angiotensin II exerts an
inhibitory influence on nNOS expression.47,57,58 Upregula-
tion of nNOS in AT1a/AT1b knockout mice was noted to
extend to the preglomerular vasculature.59 The implication of
these observations is that angiotensin II inhibits nNOS expres-
sion in macula densa and vascular smooth muscle cells just as
it inhibits COX-2 expression in the macula densa (Figure 1).
CATECHOLAMINES
In metanephric kidneys of mice with deletion of b1 and b2
adrenergic receptors, the early expression of renin in large
renal vessels is largely absent, but renin-positive cells later
appear in the typical JG arteriolar location.60 This observa-
tion implies that the early expression of renin in large renal
vessels appears to be under sympathetic control, and that the
subsequent establishment of the adult-type JG location does
not require an earlier vascular expression.
Adult b1/b2 adrenergic receptor–deficient mice have
greatly reduced levels of renin in plasma and renal tissue,
indicating that renal sympathetic input and circulating
catecholamines via b-receptors represent a dominant stimu-
latory input for basal renin expression throughout life.61
Changes of renin release by furosemide, inhibition of
angiotensin II receptors or formation, or dietary salt intake
occurred in the absence of b1/b2 adrenergic receptors, but
the magnitude of the secretory response to both acute or
chronic perturbations was markedly smaller in all condi-
tions.61 A generalizable conclusion from these and similar
observations in other studies is that the size of the releasable
renin pool as determined by renin synthesis in the entire JG
cell population is the main determinant of the amount of renin
that is released in response to an acute regulatory need (Figure 3).
Recent studies have identified two of the adenylyl cyclases
that are activated by the interaction of adrenoceptors with
Gsa. The response of renin release to an injection of
isoproterenol was significantly reduced in mice deficient in
either AC5 or AC6, suggesting that these Ca-inhibited
adenylyl cyclases are causal in the generation of cAMP that
mediates the increase in renin secretion with b-adrenergic
stimulation.62 In contrast to the b1/b2 adrenergic receptor
knockout mice, basal plasma renin and renal renin synthesis
were increased in AC6/ and normal in AC5/, indicating
redundancy and the capacity to compensate for the loss of an
individual AC.
The pituitary adenylate cyclase–activating polypeptide
stimulates renin secretion in the isolated perfused rat kidney,
as well as in JG cells in primary culture.63 This effect is
mediated by the PAC1 receptor for pituitary adenylate
cyclase–activating polypeptide, because PAC1-deficient mice
have a significantly lower plasma renin concentration and
because renin release in isolated kidneys from PAC1-deficient
mice did not respond to pituitary adenylate cyclase–activating
polypeptide.
A previously unknown role of IA-2 proteins in regulation
of renin secretion, probably in the b-adrenergic pathway, has
recently been discovered. IA-2 proteins are best known for
their role as the major autoantigen in Type I diabetes
mellitus.64,65 The structure of IA-2 and IA-2b indicates that
they are members of the tyrosine phosphatase family,
although they lack enzymatic activity.66 IA-2 proteins are
integral proteins of dense core vesicle membranes in cells
with secretory activity, as well as in autonomic nerve
varicosities and synaptic vesicles.66,67 The location of IA-2
proteins suggests a role in secretory processes, and this
notion has been confirmed with regard to the release of
insulin and luteinizing hormone LH.68–70 Plasma renin
concentration and renal renin expression were reduced by
about 50% in mice with IA-2/IA-2b double deletion, with
smaller changes in mice with the respective single deletions.71
The regulation of renin secretion by furosemide or salt intake
was intact, although the response magnitude was reduced
commensurate with the lower renin expression levels. The
effect of IA-2 and IA-2b is probably a consequence of a
reduced tonic b-adrenergic input, as the expression of IA-2
proteins colocalized with tyrosine hydroxylase, but not with
that of renin, and as b-adrenergic blockade with propranolol
did not further reduce renin secretion in the IA-deficient
animals.71 The use of IA-2 gene manipulation thus identified
an unexpected effect that indicates a contribution of IA-2 and
IA-2b to tonic adrenergic transmitter release.
ADENOSINE
The nucleoside adenosine exerts its effects throughout the
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Figure 3 |Relationship between basal plasma renin
concentration (PRC) and the increase (D) of PRC caused by
intraperitoneal (i.p.) injection of 40mg/kg furosemide. Each
symbol is the mean value of 5–10 measurements of PRC in wild-
type (purple dots) and various mutant mouse models (open
circles; mutants are used to extend the limited range of basal PRC
in wild type to the higher values of NKCC1/ and the lower
values of the other mutant strains). Data are taken from
references.37,61,71,77,94
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Over a concentration range between 1010 and 106 M,
adenosine causes dose-dependent inhibition of renin secre-
tion in isolated JG cells and kidney slices, indicating a direct
inhibitory interaction of adenosine with JG cells.72,73 Studies
with selective receptor agonists have established that the
inhibitory effect is mediated by the A1 adenosine receptor
subtype (A1AR).72,73 Mice with deletion of A1AR have
elevated plasma renin concentrations, supporting a tonic
inhibitory influence of adenosine on renin release.74–76
Interestingly, repeat measurements of plasma renin concen-
tration over a 2-week period have shown a significantly
greater variability in individual A1AR-deficient mice com-
pared with WTmice. The greater renin instability may reflect
the fact that the tubuloglomerular feedback mechanism is
absent in A1AR/ mice, and that GFR is therefore predicted
to be less stabile, resulting in greater variability of NaCl
concentration at the macula densa. Thus, the purported role
of tubuloglomerular feedback to stabilize NaCl excretion may
be achieved not only by controlling GFR, but also by
minimizing variations in renin secretion.
The role of adenosine in pressure-mediated changes in
renin secretion has been examined in A1AR-deficient mice
both in vivo and with the isolated perfused kidney.
Stimulation of renin secretion by low renal perfusion
pressure has been found to remain intact,76,77 but the
inhibitory effect of an increase in perfusion pressure on renin
secretion was entirely absent in isolated perfused kidneys.76 A
similar asymmetric effect of A1AR deficiency on renin release
pertains to the macula densa mechanism. Examination of the
stimulatory arm by furosemide-induced blockade of NaCl
transport showed maintenance of increased renin release in
A1AR-deficient mice.77,78 On the other hand, intravenous
injection of NaCl causing increased NaCl concentration and
transport at the macula densa reduced plasma renin
concentration in WT mice, but it did not alter it in A1AR
knockout mice.77 Thus, activation of A1AR by adenosine
contributes to the inhibition of renin secretion by increased
perfusion pressure or increased NaCl at the macula densa,
although the stimulatory arms of these regulatory pathways
are largely A1AR independent.
CONNEXINS
The usefulness of genetically modified mice is exemplified by
the identification of the important role of gap junctional
coupling in the function of the JG apparatus and the
regulation of renin secretion. Although it was known that the
renal vasculature and the JG cells express a number of
connexins (Cx37, Cx40, Cx43, Cx45) and that gap junctional
coupling is likely to account for electrotonic spreading of
vasomotor responses along the vasculature in general,79,80 the
use of mice with targeted deletions permitted conclusions
about the role of specific connexin proteins in renin
secretion. Cx40 is the dominant connexin linking JG cells
to each other, to neighboring mesangial cells, and to vascular
endothelial cells. Its inactivation at the gene level is associated
with dramatic abnormalities in the JG cell phenotype.81,82
In the adult animal, renal vascular renin expression is normally
restricted to cells in the media of the distal-most part of the
afferent arteriole; in Cx40-deficient mice, an expansion and
redistribution of renin-expressing cells into the extraglomer-
ular mesangium, glomerular tuft, and interstitial space is
observed.83 Together with a change toward a mesenchymal
cell appearance, this suggests cell dedifferentiation, as gap
junction coupling is a characteristic of fully differentiated
cells. Total renal renin content and plasma renin under basal
conditions were significantly elevated, indicating that gap
junctional coupling of JG cells by Cx40 exerts an inhibitory
influence, perhaps through a tonic depolarizing effect and an
upward shift of cytosolic calcium. The critical role of Cx40-
coupling among JG cells is emphasized by the finding that the
phenotype of global Cx40 deficiency is fully mimicked by JG
cell–specific deletion of Cx40,84 whereas selective deletion of
Cx40 from endothelial cells did not alter renin secretion, the
distribution of JG cells, or blood pressure.84,85 Interestingly,
elevations of plasma renin and renin mislocation were
observed in transgenic mice expressing a mutant Cx40
previously found in a patient with atrial fibrillation and
hypertension.86,87 The cause for the recruitment of ‘new’
renin-producing cells and the implicit expansion into
neighboring domains is still unknown, but this abnormality
emphasizes the restrictive effect of Cx40 coupling among
JG cells.
Baroreceptor-mediated inhibition or stimulation of renin
secretion was found to be largely obliterated in Cx40-
deficient mice, suggesting that the synchronized response of
JG cells to the pressure signal is achieved by Cx40-dependent
cell-to-cell communication.82,87 Macula densa–regulated re-
nin release as assessed by responsiveness to furosemide has
also been found to be attenuated in Cx40-deficient mice.83 As
signaling through the MD pathway is thought to involve the
release of prostaglandins and possibly of other diffusible
mediators, it is conceivable that an increased distance of
renin-producing cells from the MD imposes geometrical
restrictions to transmitter efficiency. It is important to note
that the secretory machinery itself seems to be intact,
as the stimulatory response to isoproterenol and the
inhibitory effect of No-nitro-L-arginine methyl ester were
maintained in Cx40-deficient mice.82,88 The increase in renin
production is the likely cause of the elevated blood pressure
of Cx40-deficient mice,81,82,87 although decreased levels of
eNOS expression leading to reduced NO production may
contribute to the hypertension.89
Maintenance of JG cell connectivity in the absence of Cx40
by replacing its coding sequence with that of Cx45, another
connexin isoform normally found in JG cells, resulted in
partial rescue of the Cx40-deficient phenotype.90 Plasma
renin activity was similar to WT, and it responded to
angiotensin II with a decrease and to enalapril with an
increase, changes not seen in the Cx40 null animals. As the
conductivity of Cx45 is significantly lower than that of Cx40,
these results are somewhat surprising, and they raise the
question of whether some property of the channel other than
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conductance could be responsible for the effect on renin
expression. The observation that Cx45 can substitute for
Cx40 in its role to suppress renin expression is also surprising
in view of the observation that deletion of Cx37 has no effect
on JG cell renin formation, release, or localization pattern
even though Cx37 is normally expressed by JG cells.91 The
effect of Cx45 knockin described above does not imply that
Cx45 is normally involved in the control of renin synthesis
and release. JG cell–specific deletion of Cx45 had no effect on
the RAS and did not alter blood pressure or the regulation of
renin release.92 The reason for this appears to be the absence
of demonstrable expression of Cx45 in JG cells in contrast to
arteriolar smooth muscle cells where Cx45 was readily
found.92 On the other hand, a role of Cx45 had been
suggested in studies in which Cx45 was conditionally deleted
using Cre recombinase under control of the nestin pro-
moter.93 Nestin-driven Cre activity was shown to cause reporter
expression in afferent and efferent arterioles, mesangial cells,
as well as JG cells. The phenotype of these mice largely
mimicked that of Cx40-deficient animals in that blood
pressure was elevated and renin expression and secretion was
increased. In view of the extensive spectrum of cells
expressing nestin and therefore of Cx45 deletion in other
than JG cells, the effect on the RAS in these animals may have
been exerted indirectly. Overall, participation of gap junc-
tional connectivity in renin responsiveness is in retrospect
perhaps not surprising; synchronization between ensembles
of JG cells may be necessary for physiological inputs to
cause changes in renin secretion sufficiently large to change
plasma renin.
EMERGING AREAS OF INTEREST
Inhibitors of Na–K–2Cl cotransport activity such as furose-
mide or bumetanide are potent stimulators of renin
secretion, an effect believed to be mainly due to inhibition
of the kidney-specific NKCC2 isoform and subsequent
activation of the macula densa pathway. However, a threefold
increase of basal plasma renin and renal renin mRNA has also
been observed in mice deficient in the ubiquitous NKCC1
isoform.94,95 Furthermore, cells from these mice did not show
renin exocytosis in response to furosemide. Thus, NKCC1-
mediated NaCl uptake in JG cells appears to exert direct
inhibition of basal renin production and release presumably
by determining resting membrane potential. Increased
expression of renin and elevated plasma renin concentrations
have also been observed in NHE2-deficient mice, an effect
that seems to be secondary to stimulation of the macula
densa COX-2 pathway.96 How NHE2-mediated transport
interferes with COX-2 activity still remains to be determined,
but changes in cell volume are speculated to have a
critical role.96
Significant increases in renal and plasma renin have been
found in dopamine D3-receptor-deficient mice, consistent
with the expectation that the Gi-coupled D2-like receptors
for dopamine (D2, D3, D4) inhibit renin release.97 Although
the direct effect of activation of the Gs-linked D1-like
receptors is stimulation of renin release, the D1 agonist
fenoldopam caused the opposite, a significant inhibition of
renin release.98 The mechanism of this indirect action of D1
activation appears to be inhibition of proximal tubular fluid
reabsorption and subsequent suppression of cortical expres-
sion of COX-2 by an elevated NaCl at the macula densa. D1
agonists have in fact been shown to suppress COX-2, and the
inhibition exerted by fenoldopam was converted to stimula-
tion in COX-2-deficient mice.98,99 Mice with a cell-specific
deletion of the dopamine-synthesizing enzyme aromatic
amino acid decarboxylase in the proximal tubule have an
array of disturbances that can be interpreted as representing
the unchecked effects of angiotensin II excess.100
GPR91, until now a G protein–coupled orphan receptor,
has recently been identified as a receptor for succinate. It has
been found to be localized in the apical membrane of cells
of the cortical TAL including the MD and in endothelial cells
of the afferent arteriole.101 Activation of GPR91 by succinate
stimulates COX-2 activity, PGE2 release, and presumably
renin expression, an effect that is particularly pronounced in
diabetic WT mice and markedly reduced in GPR91-deficient
animals.102
Components of the olfactory system including the
olfactory receptor Olfr90, the olfactory trimeric G protein
Golf, and the olfactory AC isoform 3 (AC3) have been found
to be expressed in MD cells.103 Plasma renin concentration in
AC3-deficient mice was reduced by about 50% compared
with WTs despite increased MD COX-2 expression and
augmented nNOS activity suggesting that the change in renin
expression was primary. The ligands that may activate
olfactory receptors on MD cells in vivo are yet to be
determined.
Gene deletion studies have clarified some functional
aspects of the issue that some mouse strains possess a single
renin gene (Ren-1c), whereas other strains in addition carry a
duplicated renin gene (Ren-1d and Ren-2). Deletion of the
Ren-1d gene in two renin gene mice has shown that Ren-2
generates a fully functional renin providing sufficiently high
levels of active plasma renin to essentially keep arterial blood
pressure normal.104,105 Because Ren-2 expression is known to
be androgen sensitive, this effect is somewhat less effective in
female animals. Nevertheless, an important characteristic of
Ren-1d deficiency is that plasma levels of prorenin are
markedly elevated and that the granulation of JG cells
appears to be reduced.104 Thus, Ren-2 does not seem to carry
the signals needed to be sorted to the regulated secretory
pathway, but is preferentially secreted as prorenin through
the constitutive pathway.
Cathepsin B is able to activate prorenin in vitro, and it has
been considered a likely candidate as physiological prorenin-
processing enzyme because of its localization in JG cell
granules.106 However, mice with deletions of the cathepsin B
gene have normal plasma levels of active renin and do not
display any of the phenotypic hallmarks of renin defi-
ciency.107 Thus, the issue of the prorenin activator in vivo still
awaits resolution.
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Isolated JG cells respond to hypotonicity-induced cell
swelling with an increase in renin secretion. Recent studies
using membrane capacitance changes as index of exocytosis
have shown that the increase in capacitance caused by
hypotonicity in JG cells from WT mice was absent in cells
from COX-2-deficient or AQP1-deficient mice.108 These
observations indicate that hypotonicity causes water influx
through AQP1 water channels, activation of COX-2, release
of PGE2, and stimulation of renin exocytosis through the
cAMP/PKA pathway. The novel findings of the presence of
both COX-2 and AQP1 in JG cells and of their functional
interactions have interesting implications that will stimulate
further investigations.
CONCLUSION
Genetic modification in mice has become the ultimate tool
for the in vivo evaluation of the chronic effects of complete
and ‘certified’ inactivation of defined regulatory factors.
Given the central role of the RAS in body fluid and blood
pressure regulation, it is not surprising that mutational
approaches have been extensively used to gain further
insights into this system. Improved understanding has been
gained of the feedback inhibition of renin expression by
angiotensin II, the central role of Gsa signaling in renin
control, the inclusion of COX-2 and nNOS products in
regulatory pathways, the inhibitory role of adenosine in
baroreceptor and macula densa control, and the fundamental
contribution of b-receptors to renin expression. New
directions that have greatly benefited from the availability
of novel mouse models include exciting information on the
roles of connexins, GPR91, AC3, specific transport proteins,
and numerous other factors. Combined with vastly improved
phenotypic methods, the insights gained have been pro-
found, confirming some hypotheses and dashing others.
Insights with the ‘first generation’ methodology of global
over- or underexpression of genes have been important, but
one may expect that widened application of improved tools
for temporal and spatial control, as well as insertions of
known mutations will further expand the application of this
approach. The expected extension of gene manipulations
from mice to rats will be highly welcome in that it will
facilitate and expand the phenotyping possibilities.109
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